ABAlexandre Lemos Bortolotto

Alexandre Lemos Bortolotto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandre Lemos Bortolotto has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Richard L. Verrier

    Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, MA

    7 shared publications
  • Alexandre A. Marum

    Beth Israel Deaconess Medical Center, Boston, MA, USA,; Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

    5 shared publications
  • Luiz Belardinelli

    InCarda Therapeutics, Inc, Newark, CA

    5 shared publications
  • Bruna Araujo Silva

    Beth Israel Deaconess Medical Center, Boston, MA, USA,; Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

    4 shared publications
  • Fernanda Tessarolo Silva

    Beth Israel Deaconess Medical Center, Boston, MA, USA,; Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

    4 shared publications
  • Anderson C. Silva

    Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Environmental Sciences, Harvard School of Public Health, Boston, MA, United States of America; Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

    3 shared publications

Latest Publications

  • Reversal of Severe Cardiorenal Dysfunction After Correction of Late-Onset Aortic Obstruction in an Adult Patient

    by Alexandre L. Bortolotto, Rogério B.R. Filho, Everton L. dos Santos Moreira, Paula C.C. Gonçalves, Luis A.O. Dallan, Luiz A. Bortolotto

  • Open Access

    Association between Arterial Stiffness and Higher Burden of Atrial Arrhythmia in Elderly Hypertensive Patients without Atrial Fibrillation

    by João Gabriel B. Lage, Alexandre L. Bortolotto, Luiz A. Bortolotto, Renata G. S. Verardino, Gabrielle D. Pessente, David C. S. Le Bihan, Rodrigo B. M. Barretto, Fernanda M. Consolim-Colombo, Denise T. Hachul, Luciana Sacilotto, et al.

    Background: Increased arterial stiffness is currently an independent risk factor for atrial fibrillation, but the pathophysiological mechanisms of this arrhythmia remain an area of knowledge gap to be explored. Objectives: To investigate the existence of an association between arterial stiffness and the density of premature atrial contractions (PACs) in hypertensive individuals without atrial fibrillation. Methods: Cross-sectional study with hypertensive patients without diagnosed atrial fibrillation, who were studied with speckle-tracking echocardiography to assess left atrial (LA) strain and carotid-femoral pulse wave velocity (cfPWV) to assess arterial stiffness. All patients underwent 24h-ECG Holter and laboratory tests. Significance level was set at p<0.05. Results: Seventy participants from a single centre without overt cardiovascular disease were included. The cfPWV was correlated with higher density of PACs in 24h-Holter monitoring, independently of LV mass index (1.48 [1.08-2.03], p-value 0.005). Increased cfPWV was correlated with decreased LA strain values, with Spearman correlation coefficients of −0.27 (p-value 0.027) and −0.29 (p-value 0.018) for reservoir and conduit 2D Strain, respectively. Conclusions: In this study with hypertensive patients, it was possible to demonstrate an association between arterial stiffness and higher density of atrial arrhythmias. Furthermore, arterial stiffness was associated with lower left atrial strain values for reservoir and conduit functions.

  • Open Access

    Associação entre Rigidez Arterial e Maior Densidade de Arritmia Atrial em Idosos Hipertensos sem Fibrilação Atrial

    by João Gabriel B. Lage, Alexandre L. Bortolotto, Luiz A. Bortolotto, Renata G. S. Verardino, Gabrielle D. Pessente, David C. S. Le Bihan, Rodrigo B. M. Barretto, Fernanda M. Consolim-Colombo, Denise T. Hachul, Luciana Sacilotto, et al.

    Resumo Fundamento: A rigidez arterial aumentada é considerada atualmente um fator de risco independente para fibrilação atrial. No entanto, os mecanismos fisiopatológicos dessa arritmia ainda constituem uma lacuna no conhecimento a ser explorada. Objetivos: Investigar a existência de uma associação entre rigidez arterial e densidade de extrassístoles atriais em indivíduos hipertensos sem fibrilação atrial. Métodos: Estudo transversal com pacientes hipertensos sem fibrilação atrial diagnosticada, que foram estudados com ecocardiografia speckle-tracking para avaliar o strain do átrio esquerdo e velocidade de onda de pulso carótido-femoral (VOPcf) para avaliar a rigidez arterial. Todos os pacientes foram submetidos ao Holter de 24 horas e exames laboratoriais. O nível de significância adotado foi de p<0,05. Resultados: Setenta pacientes de um único centro sem doença cardiovascular evidente foram incluídos. A VOPcf correlacionou-se com uma maior densidade de extrassístoles atriais no Holter de 24 horas, independentemente da massa ventricular esquerda [1,48 (1,08- 2,03), p = 0,005]. Uma VOPcf aumentada correlacionou-se com valores reduzidos de strain atrial esquerdo, com coeficientes de correlação de Spearman de −0,27 (p= 0,027) e −0,29 (p = 0,018) para strains bidimensionais de reservatório e de conduto, respectivamente. Conclusão: Neste estudo com pacientes hipertensos, foi possível demonstrar uma associação entre rigidez arterial e maior densidade de arritmias atriais. Além disso, a rigidez arterial associou-se com valores mais baixos de strain atrial esquerdo das funções de reservatório e de conduto.


  • Open Access

    Arterial stiffness and atrial fibrillation: A review

    by João Gabriel Batista Lage, Alexandre Lemos Bortolotto, Mauricio Ibrahim Scanavacca, Luiz Aparecido Bortolotto, Francisco Carlos da Costa Darrieux


  • Preimplantation interlead ECG heterogeneity is superior to QRS complex duration in predicting mechanical super-response in patients with non–left bundle branch block receiving cardiac resynchronization therapy

    by Alexandre L. Bortolotto, Richard L. Verrier, Bruce D. Nearing, Alexandre A. Marum, Bruna Araujo Silva, Giovanna C. Pedreira, Fernanda Tessarolo Silva, Sofia A. Medeiros, Jakub Sroubek, Peter J. Zimetbaum, et al.


  • Regadenoson-induced T-wave heterogeneity complements coronary stenosis detection by myocardial perfusion imaging in men and women

    by Bruna Araujo Silva, Thomas H Hauser, Bruce D Nearing, Alexandre L Bortolotto, Alexandre A Marum, Fernanda Tessarolo Silva, Sofia A Medeiros, Giovanna C Pedreira, Ernest V Gervino, Richard L Verrier

    Aims : We analysed whether incorporating electrocardiographic interlead T-wave heterogeneity (TWH) with myocardial perfusion imaging (MPI) during pharmacologic stress improves detection of flow-limiting lesions (FLL). Methods and results : Medical records of all 103 patients at our institution who underwent stress testing with regadenoson (0.4 mg IV bolus) within 3 months of coronary angiography from September 2017 to March 2019 were studied. Cases (N = 59) had angiographically significant FLL (≥50% of left main or ≥70% of other epicardial coronary arteries ≥2 mm in diameter); controls (N = 44) were normal or had non-FLL. TWH, i.e., interlead splay of T waves, was assessed from precordial leads V4–6 by second central moment analysis. Maximum TWHV4–6 levels during regadenoson stress were 68% higher in cases than in controls (P < 0.0001). TWHV4–6 generated areas under the receiver-operating characteristic (ROC) curve of 0.79 in men (P < 0.0001) and 0.71 in women (P = 0.007). In men, the ROC-guided 54-µV TWHV4–6 cut-point for FLL produced adjusted odds of 7.3 [95% confidence interval (CI): 1.3–41.5, P = 0.03], 79% sensitivity, and 78% specificity. In women, the ROC-guided 35-µV TWHV4–6 cut-point produced adjusted odds of 4.5 (95% CI: 1.1–18.9, P = 0.04), 84% sensitivity, and 52% specificity. Adding TWHV4–6 to MPI determinations reduced false-positive results by 70%, more than doubled true-negative results, and improved adjusted odds ratio to 6.8 (95% CI: 2.2–21.4, P = 0.001) with specificity of 78% in men and 86% in women. Conclusion : This observational study is the first to demonstrate the benefit of combining TWHV4–6 with MPI to enhance FLL detection during MPI with regadenoson in both men and women.


  • Pulmonary Delivery of Metoprolol Reduces Ventricular Rate During Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm

    by Alexandre A. Marum, Bruna Araujo Silva, Alexandre L. Bortolotto, Giovanna C. Pedreira, Fernanda Tessarolo Silva, Sofia A. Medeiros, Bruce D. Nearing, Luiz Belardinelli, Richard L. Verrier

    Background: Safe, effective pulmonary delivery of cardioactive agents in humans is under development. Objectives: We examined whether intratracheal delivery of metoprolol can reduce ventricular rate during atrial fibrillation (AF) and accelerate conversion to sinus rhythm. Methods: In 7 closed-chest, anesthetized Yorkshire pigs, AF was induced by intrapericardial infusion of acetylcholine (1 mL of 102.5-mM solution) followed by atrial burst pacing and was allowed to continue for 2 minutes before intratracheal instillation of sterile water or metoprolol (0.2-mg/kg bolus) using a catheter positioned at the bifurcation of the main bronchi. High-resolution electrograms were obtained from catheters fluoroscopically positioned in the right atrium and left ventricle. Results: Rapid intratracheal instillation of metoprolol caused a 32-beat/min reduction in ventricular rate during AF (from 272 ± 13.7 to 240 ± 12.6 beats/min, P = 0.008) and a 2.3-minute reduction in AF duration (from 10.3 ± 2.0 to 8.0 ± 1.4 minutes, P = 0.018) compared with sterile water control. Conversion of AF to sinus rhythm was associated with rapid restoration (5–6 minutes) of heart rate and arterial blood pressure toward control values. Intratracheal metoprolol reduced AF dominant frequency by 31% (from 8.7 ± 0.9 to 6.0 ± 1.1 Hz, P = 0.04) compared with control and resulted in a trend toward a 5% increase in PR interval (from 174 ± 11.2 to 182 ± 11.4 ms, P = 0.07). Conclusions: Intratracheal delivery of metoprolol effectively reduces ventricular rate during AF and accelerates conversion to normal sinus rhythm in a pig model of acetylcholine-induced AF.


  • Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation

    by Fernanda Tessarolo Silva, Giovanna C. Pedreira, Sofia A. Medeiros, Alexandre L. Bortolotto, Bruna Araujo Silva, Michael Hurrey, Prashanti Madhavapeddi, Carlos Schuler, Luiz Belardinelli, Richard L. Verrier

    Introduction: Inhaled flecainide significantly alters atrial electrical properties with the potential to terminate atrial fibrillation (AF) efficiently by optimizing dose and drug formulation.Methods: Seventeen Yorkshire pigs were studied. Intrapericardial acetylcholine and burst pacing were used to induce AF. Effects of a novel cyclodextrin formulation (hydroxypropyl‐ß‐cyclodextrin [HPßCD]) of flecainide (75 mg/mL, 0.5 or 1.0 mg/kg, bolus) instilled intratracheally at 2 minutes after AF initiation were studied. Concentration time‐area analyses of flecainide HPßCD were compared to the traditional acetate formulation.Results: Intratracheal instillation of flecainide HPßCD accelerated the conversion of AF to sinus rhythm in a dose‐proportional manner, shortening AF duration by 47% (P = .014) and 79% (P = .002) at the lower and higher doses, respectively, compared to intratracheal sterile water placebo. AF dominant frequency was reduced by 11% (P = .04) and 29% (P = .004) respective to dose. At 2 minutes after intratracheal flecainide HPßCD, atrial depolarization (Pa) duration increased by 12% (P = .02) and 17% (P = .009) at the lower and higher doses, respectively. At this time, the PR interval was prolonged by 9% (P = .04 for the higher dose) and AV node conduction was slowed, decreasing the ventricular rate during AF by 16% (P = .002) and 28% (P = .007) for the lower and higher doses. Flecainide HPßCD achieved the more efficient conversion of AF than the acetate formulation, reflected in a markedly reduced area under the curve (P = .04).Conclusion: Intratracheal instillation of the new flecainide HPßCD formulation effectively terminates AF through efficient multimodal actions including slowing of atrial conduction velocity and decreasing AF dominant frequency, allowing reduced net drug delivery and inhalation time.


  • Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration

    by Alexandre A. Marum, Bruna A. Silva, Alexandre L. Bortolotto, Anderson C. Silva, Victor Z. de Antonio, Luiz Belardinelli, Richard L. Verrier


  • Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model

    by Richard L. Verrier, Alexandre L. Bortolotto, Bruna A. Silva, Alexandre A. Marum, Fernando G. Stocco, Ederson Evaristo, Victor Z. de Antonio, Anderson C. Silva, Luiz Belardinelli